Perimeter Medical Imaging AI, Inc.

OTCPK:PYNK.F Stock Report

Market Cap: US$44.1m

Perimeter Medical Imaging AI Valuation

Is PYNK.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PYNK.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate PYNK.F's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PYNK.F's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PYNK.F?

Key metric: As PYNK.F barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for PYNK.F. This is calculated by dividing PYNK.F's market cap by their current book value.
What is PYNK.F's PB Ratio?
PB Ratio3.2x
BookUS$12.80m
Market CapUS$44.12m

Price to Book Ratio vs Peers

How does PYNK.F's PB Ratio compare to its peers?

The above table shows the PB ratio for PYNK.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average4.6x
NMTC NeuroOne Medical Technologies
7.2xn/aUS$22.5m
ECOR electroCore
6.8x70.2%US$64.1m
HYPR Hyperfine
1.2x6.9%US$65.4m
POCI Precision Optics Corporation
3.2xn/aUS$34.0m
PYNK.F Perimeter Medical Imaging AI
3.2x-12.8%US$61.6m

Price-To-Book vs Peers: PYNK.F is good value based on its Price-To-Book Ratio (3.2x) compared to the peer average (4.6x).

Price to Book Ratio vs Industry

How does PYNK.F's PB Ratio compare vs other companies in the US Medical Equipment Industry?

28 CompaniesPrice / BookEstimated GrowthMarket Cap
ADGM Adagio Medical Holdings
0.4xn/aUS$29.07m
RVP Retractable Technologies
0.2xn/aUS$17.55m
MHUA Meihua International Medical Technologies
0.1xn/aUS$16.93m
LFWD Lifeward
0.5x65.0%US$16.30m
PYNK.F 3.2xIndustry Avg. 2.5xNo. of Companies28PB0246810+
28 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: PYNK.F is expensive based on its Price-To-Book Ratio (3.2x) compared to the US Medical Equipment industry average (2.5x).

Price to Book Ratio vs Fair Ratio

What is PYNK.F's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PYNK.F PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio3.2x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate PYNK.F's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PYNK.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$0.53
US$1.43
+169.6%
35.4%US$2.15US$1.07n/a3
Nov ’25US$0.33
US$2.99
+817.8%
63.6%US$4.89US$1.09n/a2
Oct ’25US$0.40
US$2.25
+462.1%
84.3%US$4.92US$0.73n/a3
Sep ’25US$0.23
US$2.25
+886.7%
84.3%US$4.92US$0.73n/a3
Aug ’25US$0.34
US$2.25
+560.6%
84.3%US$4.93US$0.73n/a3
Jul ’25US$0.25
US$2.25
+807.5%
84.3%US$4.93US$0.73n/a3
Jun ’25US$0.40
US$2.84
+609.1%
74.2%US$4.94US$0.73n/a2
May ’25US$0.37
US$2.84
+657.7%
74.2%US$4.94US$0.73n/a2
Apr ’25US$0.65
US$3.22
+399.3%
54.3%US$4.97US$1.47n/a2
Mar ’25US$0.72
US$2.71
+275.7%
56.8%US$4.87US$1.44n/a3
Feb ’25US$0.78
US$2.71
+246.4%
56.8%US$4.87US$1.44n/a3
Jan ’25US$0.95
US$2.71
+185.8%
56.8%US$4.87US$1.44n/a3
Dec ’24US$0.64
US$2.71
+323.2%
56.8%US$4.87US$1.44n/a3
Nov ’24US$0.70
US$2.71
+286.4%
56.8%US$4.87US$1.44US$0.333
Oct ’24US$0.92
US$2.76
+201.0%
56.8%US$4.96US$1.47US$0.403
Sep ’24US$1.00
US$2.76
+176.4%
56.8%US$4.96US$1.47US$0.233
Aug ’24US$1.22
US$2.65
+117.0%
52.6%US$5.02US$1.49US$0.344
Jul ’24US$1.36
US$2.65
+95.4%
52.6%US$5.02US$1.49US$0.254
Jun ’24US$1.28
US$2.65
+107.2%
52.6%US$5.02US$1.49US$0.404
May ’24US$1.42
US$2.65
+87.1%
52.6%US$5.02US$1.49US$0.374
Apr ’24US$1.19
US$3.05
+156.2%
42.3%US$5.06US$1.50US$0.654
Mar ’24US$1.23
US$3.05
+147.8%
42.3%US$5.06US$1.50US$0.724
Feb ’24US$1.20
US$3.05
+154.0%
42.3%US$5.06US$1.50US$0.784
Jan ’24US$1.18
US$3.05
+158.3%
42.3%US$5.06US$1.50US$0.954
Dec ’23US$0.95
US$3.05
+220.8%
42.3%US$5.06US$1.50US$0.644
Nov ’23US$1.02
US$4.25
+316.2%
18.6%US$5.22US$3.09US$0.704

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Elevance Health

US$92.2b

Operates as a health benefits company in the United States.

ELV

US$403.60

7D

-0.8%

1Y

-15.9%

Centene

US$29.8b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

CNC

US$60.35

7D

2.8%

1Y

-18.7%

electroCore

US$64.1m

A commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally.

ECOR

US$9.92

7D

-27.1%

1Y

80.4%